Biogen (BIIB) Current Deferred Revenue (2010 - 2012)

Biogen's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $110.3 million for Q2 2012.

• In Q2 2012, Current Deferred Revenue changed N/A year-over-year to $110.3 million; the TTM figure through Jun 2012 stood at $110.3 million (changed N/A YoY), while the FY2011 annual figure was $69.6 million, up 68.52% from the prior year.
• Current Deferred Revenue was $110.3 million for Q2 2012 at Biogen, up from $96.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $110.3 million in Q2 2012 to a low of $41.3 million in Q4 2010.
• Historically, Current Deferred Revenue has averaged $79.3 million across 3 years, with a median of $82.8 million in 2011.
• Biggest YoY gain for Current Deferred Revenue was 68.52% in 2011; the steepest drop was 68.52% in 2011.
• A 3-year view of Current Deferred Revenue shows it stood at $41.3 million in 2010, then jumped by 68.52% to $69.6 million in 2011, then surged by 58.48% to $110.3 million in 2012.
• The last three Current Deferred Revenue figures came in at $110.3 million (Q2 2012), $96.0 million (Q1 2012), and $69.6 million (Q4 2011), per Business Quant data.